InsiderClue
Stocks · Health care · Pharmaceutical Preparations

MoonLake Immunotherapeutics

MLTX Clue Score35
Switzerland Fiscal year ends December CIK 0001821586
$10.82 +2.27% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $10.82 +8.20% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 20 Oct 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−4.6Net income−4.5Fiscal year 2022Operating income−65.1Net income−50.0EPS, diluted−1.70Fiscal year 2023Operating income−54.1Net income−36.0EPS, diluted−0.73Fiscal year 2024Operating income−143.1Net income−118.9EPS, diluted−1.89Fiscal year 2025Operating income−244.8Net income−227.3EPS, diluted−3.53
FY2021FY2022FY2023FY2024FY2025
Operating income −4.6 −65.1 −54.1 −143.1 −244.8
Net income −4.5 −50.0 −36.0 −118.9 −227.3
Growth
EPS, diluted n/a −1.70 −0.73 −1.89 −3.53

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−0.6Fiscal year 2022Operating cash flow−55.9Capital expenditure−0.0Free cash flow−55.9Buybacks0.0Fiscal year 2023Operating cash flow−42.8Capital expenditure−0.3Free cash flow−43.1Buybacks0.0Fiscal year 2024Operating cash flow−116.6Capital expenditure−0.5Free cash flow−117.1Buybacks−0.0Fiscal year 2025Operating cash flow−196.0Capital expenditure−0.0Free cash flow−196.0
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.6 −55.9 −42.8 −116.6 −196.0
Capital expenditure n/a −0.0 −0.3 −0.5 −0.0
Free cash flow n/a −55.9 −43.1 −117.1 −196.0
Growth
Buybacks n/a 0.0 0.0 −0.0 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2021Cash8.0Shareholders’ equity−11.6Fiscal year 2022Cash39.5Shareholders’ equity48.9Fiscal year 2023Cash451.2Shareholders’ equity495.7Fiscal year 2024Cash180.4Total debt0.0Net cash (debt)180.4Shareholders’ equity446.8Debt to equity0.00Fiscal year 2025Cash334.5Total debt74.1Net cash (debt)260.4Shareholders’ equity304.5Debt to equity0.24
FY2021FY2022FY2023FY2024FY2025
Cash 8.0 39.5 451.2 180.4 334.5
Total debt n/a n/a n/a 0.0 74.1
Net cash (debt) n/a n/a n/a 180.4 260.4
Shareholders’ equity −11.6 48.9 495.7 446.8 304.5
Debt to equity n/a n/a n/a 0.00 0.24

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 42.0 31.8 112.8 202.9
4.6 23.0 22.3 30.3 42.0
−4.6 −65.1 −54.1 −143.1 −244.8
Growth
n/a −64.5 −44.0 −121.0 −229.7
n/a 0.0 0.1 0.3 0.6
−4.5 −50.0 −36.0 −118.9 −227.3
Growth
Per share
n/a −1.70 −0.73 −1.89 −3.53
n/a −1.70 −0.73 −1.89 −3.53
Growth
n/a 29.4 49.1 62.9 64.5
360.0 29.4 49.1 62.9 64.5
Growth −91.8% +67.3% +28.0% +2.5%

† The diluted share count jumps at 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 5 of 5 years on file.